Questions about medication safety during pregnancy often travel faster than the science meant to answer them. Many expectant parents worry about whether common pain relievers could affect a child’s long-term development. Because Tylenol is one of the most widely used medications during pregnancy, it has received particular scrutiny from researchers who study prenatal health and childhood outcomes.
A large study published in JAMA Network Open was conducted by researchers at Drexel University. The researchers analyzed pregnancy and child development data. They found no clear evidence linking prenatal acetaminophen use with autism spectrum disorder after accounting for genetic and family factors.
Findings like these help doctors reassure patients about medication safety during pregnancy. They show that commonly recommended treatments can still play a safe role in managing pain and fever when used appropriately.
The giant JAMA sibling study that changed the story
One of the most influential analyses appeared in JAMA in 2024. Researchers from the Karolinska Institutet and collaborating Swedish universities conducted the study.
They examined national health records covering more than 2.4 million children and about 1.2 million birthing parents. Their approach compared siblings within the same family where one pregnancy involved acetaminophen exposure and another did not.
This design allowed investigators to account for shared genetics and family circumstances that ordinary observational studies cannot fully capture. In the simplest statistical models, the differences appeared small but noticeable. Autism risk at age ten was about 1.53 percent among children exposed to acetaminophen during pregnancy compared with 1.33 percent among those who were not.
Yet once researchers applied sibling comparison methods, the association vanished. The hazard ratios for autism were 0.98, ADHD 0.98, and intellectual disability 1.01, respectively. The authors concluded that the relationship was likely noncausal and explained instead by parental health characteristics and socioeconomic differences.
NIH: “No causal link” in over 2 million children
Another major analysis supported the same conclusion. A 2025 report supported by the National Institutes of Health examined Swedish registry data involving more than two million children.
The dataset overlapped with the population analyzed in the earlier JAMA research. The researchers used additional statistical approaches to address potential confounding factors.
Investigators reported that prenatal acetaminophen exposure was not linked to an increased risk of autism, ADHD, or intellectual disability. They reached this conclusion after adjusting for parental psychiatric history, socioeconomic variables, and other health characteristics.
The National Institutes of Health summary of the research explained the findings in detail. It emphasized that earlier observational signals likely reflected differences between families rather than a direct neurodevelopmental effect of the medication itself.
ACOG’s blunt statement: no reputable study has proved causation
Professional medical organizations have also weighed in as the research accumulated. The American College of Obstetricians and Gynecologists issued a statement addressing concerns about acetaminophen use during pregnancy. The group warned that alarmist claims about acetaminophen and autism can confuse pregnant patients who rely on the medication for legitimate medical reasons.
Leaders at the American College of Obstetricians and Gynecologists addressed the topic in their public guidance. They noted that more than two decades of research have not produced a reputable study showing that acetaminophen use during pregnancy causes neurodevelopmental disorders.
Their clinical guidance specifically highlights the 2024 JAMA sibling study and another high-quality analysis as the most rigorous examinations of the question. Both found no meaningful association after accounting for genetic and shared environmental factors.
When you only include low-bias studies, the signal disappears
Another perspective emerged from a 2025 review published in The Lancet, which examined the extensive literature on prenatal paracetamol exposure and child neurodevelopment. Researchers evaluated dozens of studies and then narrowed their analysis to those judged to have the lowest risk of bias.
Within this stricter group, the associations largely vanished. The analysis reported odds ratios close to one for autism spectrum disorder, ADHD, and intellectual disability. The numbers suggested no meaningful relationship between prenatal acetaminophen exposure and these conditions.
The pattern closely resembled that observed in the JAMA sibling study. Weak signals appear in looser observational work but fade when stronger controls are applied.
Why earlier “Tylenol causes autism” headlines were misleading
Some of the early alarms originated from a widely cited meta-analysis of six European birth cohorts. That review reported roughly 19 percent higher odds of autism related symptoms and 21 percent higher odds of ADHD symptoms among children exposed to acetaminophen in utero.
However, the details told a more complicated story. The meta-analysis relied heavily on a single large cohort from the European birth cohort collaboration, the Avon Longitudinal Study of Parents and Children.
When researchers looked at the other cohorts individually, none found statistically significant associations. Authors of the 2024 JAMA paper later argued that these modest signals likely reflected unmeasured confounding rather than a true biological effect.
Confounding 101: It is not just the pill, it is the reason you take it
Save this article
Enter your email address and we'll send it straight to your inbox.
One of the central insights from the JAMA sibling study concerns confounding. People who take more acetaminophen during pregnancy often differ in meaningful ways from those who do not. They may experience more frequent infections, chronic pain, stress, or other health conditions requiring treatment.
The Karolinska Institutet researchers emphasized that no single factor explained the earlier associations. Instead, many small differences in parental health and social conditions likely accumulated, creating the illusion of risk.
By comparing siblings raised in the same family environment, the analysis controlled for many background differences. Once that adjustment occurred, the apparent link between acetaminophen and autism disappeared.
What national and international groups are actually telling parents
Public health guidance has gradually converged as stronger data emerged. A 2025 evidence review published by the University of Utah Drug Information Service summarized recommendations from national and international medical organizations.
The review concluded that current evidence does not support a causal relationship between prenatal acetaminophen exposure and autism, ADHD, or intellectual disability. It also noted that the American Academy of Pediatrics and ACOG continue to support occasional, medically directed use of acetaminophen during pregnancy. Both organizations emphasize appropriate dosing and consultation with healthcare providers.
Meanwhile, some studies still recommend caution
Scientific debates rarely close entirely. A 2025 systematic review was published in BMC Environmental Health. The study was led by researchers from Harvard University and the Icahn School of Medicine at Mount Sinai. The review pooled results from 46 studies and reported evidence of an association between prenatal acetaminophen exposure and certain neurodevelopmental outcomes.
The authors noted that the association appeared strongest when acetaminophen was used for four weeks or longer. They recommended cautious use rather than elimination. The guidance emphasized the lowest effective dose for the shortest possible duration under medical supervision.
The same paper also addressed the importance of treating fever during pregnancy. It acknowledged that acetaminophen remains important because untreated high fever carries known risks, including neural tube defects.
The expert balancing act: pain and fever versus theoretical risks
Medical guidance often involves balancing competing risks. Untreated pain and fever during pregnancy can harm both the pregnant person and the developing fetus. For that reason, acetaminophen has long been considered the first-line medication when treatment becomes necessary.
The American College of Obstetricians and Gynecologists advises occasional use at the lowest effective dose for the shortest necessary time. Researchers at Mount Sinai, even while encouraging caution for heavy or prolonged exposure, have similarly told patients not to stop medication without consulting clinicians. Their public statements emphasize weighing real medical needs against theoretical risks.
Autism risk in context: what families are actually facing
Autism prevalence has increased in recent decades, a trend largely attributed to broader diagnostic criteria and improved awareness. Public health reports from the Centers for Disease Control and Prevention Autism and Developmental Disabilities Monitoring Network examine trends in autism diagnoses. The reports explain that expanded screening and changing definitions contribute to rising reported numbers.
The Swedish JAMA cohort analysis helps place the debate in context. Before the sibling adjustment, the difference in autism risk between exposed and unexposed children was only about two-tenths of a percentage point.
After accounting for family factors, the difference disappeared entirely. The framing matters because even the least controlled models showed very small absolute differences.
Why “no evidence of harm” does not mean take it for everything
Professional organizations emphasize nuance rather than absolutes. The National Institutes of Health and ACOG do not recommend taking acetaminophen for every minor discomfort during pregnancy. Their position is more measured.
The consensus emerging from decades of research suggests that reasonable, medically guided use has not been shown to cause autism. At the same time, clinicians still advise avoiding unnecessary medications whenever possible. The message reflects a careful middle ground between internet-driven panic and responsible medical caution.
Key takeaway
The newest generation of research is reshaping the narrative around acetaminophen use during pregnancy. Large sibling comparison studies published in JAMA have examined prenatal acetaminophen exposure and autism risk. These investigations consistently find that the apparent link disappears when genetic and environmental confounding factors are properly controlled.
That conclusion does not mean medication should be used casually. Physicians continue to recommend the lowest effective dose for the shortest necessary time, ideally under medical guidance. Yet the growing body of data suggests that earlier headlines overstated the risk.
When researchers account for family background, parental health, and the reasons people take the drug, the results change significantly. The evidence increasingly indicates that acetaminophen itself is not driving autism risk.
Disclaimer – This list is solely the author’s opinion based on research and publicly available information. It is not intended to be professional advice.
Like our content? Be sure to follow us
